SCHEMBL14698129

SCHEMBL14698129

CC(=O)Oc1cccc(-c2ocnc2-c2nc(-c3ccccc3)c(-c3ccccc3)o2)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.74
ALDH1A1 P00352 3/20 0.74
MEN1 O00255 2/20 0.74
KMT2A Q03164 2/20 0.74
CYP1A2 P05177 1/20 0.74
CYP3A4 P08684 1/20 0.74
CYP2D6 P10635 1/20 0.74
HPGD P15428 1/20 0.74
HSD17B10 Q99714 1/20 0.74
FABP4 P15090 2/20 0.52
LMNA P02545 3/20 0.49
MAPT P10636 1/20 0.49
RXRA P19793 4/20 0.45
RXRB P28702 4/20 0.45
ADORA2A P29274 1/20 0.45
PTGIR P43119 3/20 0.45
HTT P42858 1/20 0.42
RECQL P46063 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19163857 0.88 KDM4E (0.85) KDM4EALDH1A1MEN1KMT2ACYP1A2
SCHEMBL674739 0.85 KDM4E (1.00) KDM4EALDH1A1MEN1KMT2ACYP1A2
SCHEMBL29640642 0.85 KDM4E (1.00) KDM4EALDH1A1MEN1KMT2ACYP1A2
SCHEMBL9594904 0.82 KDM4E (0.72) KDM4EALDH1A1MEN1KMT2ACYP1A2
SCHEMBL27952162 0.79 KDM4E (0.65) KDM4EALDH1A1MEN1KMT2ACYP1A2
SCHEMBL9127459 0.77 KDM4E (0.59) KDM4EALDH1A1MEN1KMT2ACYP1A2
SCHEMBL9006760 0.75 PTGIR (0.73) KDM4EALDH1A1MEN1KMT2ACYP1A2
SCHEMBL9593239 0.75 ALDH1A1 (0.80) KDM4EALDH1A1MEN1KMT2ACYP1A2
SCHEMBL9592678 0.75 KDM4E (0.65) KDM4EALDH1A1MEN1KMT2ACYP1A2
SCHEMBL9452960 0.75 PPARD (0.56) KDM4ECYP3A4HPGDFABP4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11318331-B2 Pulmonary hypertension treatment SONIVIE LTD. (IL) 2022-05-03 US disclosed
US-20200368244-A1 PULMONARY HYPERTENSION TREATMENT Sonie Vie Ltd. (IL) 2020-11-26 US disclosed
EP-3600434-A1 PULMONARY HYPERTENSION TREATMENT Sonievie Ltd. (IL) 2020-02-05 EP disclosed
WO-2018173052-A1 PULMONARY HYPERTENSION TREATMENT SONIEVIE LTD. (IL) 2018-09-27 WO disclosed
EP-3278112-A2 A COMPOSITION COMPRISING PROSTACYCLIN OR ANALOGUES THEREOF FOR TREATMENT OF ACUTE CRITICALLY ILL PATIENTS Ostrowski, Sisse Rye (DK) 2018-02-07 EP disclosed
WO-2016156107-A2 A COMPOSITION COMPRISING PROSTACYCLIN OR ANALOGUES THEREOF FOR TREATMENT OF ACUTE CRITICALLY ILL PATIENTS RIGSHOSPITALET (DK) 2016-10-06 WO disclosed
EP-2741738-A1 SUSTAINED RELEASE COMPOSITION OF PROSTACYCLIN Ascendis Pharma A/S (DK) 2014-06-18 EP disclosed
WO-2013024051-A1 SUSTAINED RELEASE COMPOSITION OF PROSTACYCLIN ASCENDIS PHARMA A/S (DK) 2013-02-21 WO disclosed